DDS ResearchThe Central Research Institute of Daewon Pharm has been actively performing studies on the drug delivery system of release control or long acting medicine, and the solubilization system for poorly water-soluble drugs. Following the results of such studies, products modified in dosage form or method have been released.
The representative productspresented by the Central Research Institute includes Pelubi SR Tab, Otillen F Tab, Renamezin Cap, and Daewon Megastrol ES Suspension. Pelubi SR Tab is the incrementally modified drug of Pelubi Tab, the 12th domestic newmedicine containing pelubiprofen. This modified drug minimizes side effects on gastrointestinal tract and greatly improves dosing convenience by reducing the number of dosing to twice a day. Otillen F Tabapplies the company’s patent floating technology within stomach to elongate the stay time of drug in stomach up to 18 times compared to other products. Renamezin Cap is the modified capsule-type medicine of existing granule-type activated carbon adsorption used for the delay of dialysis to greatly improve dosing convenience and the adsorption rate of urotoxic substances. Daewon Megastrol ES Suspension is evaluated to substantially increase the absorption rate in the body using nano conversion technology.
In addition, to improve dosing convenience for children and the elderly, the Central Research Institute has devoted itself to the study of syrup and suspension, and finally established the system of suspension manufacturing, which is now applied to produce the liquid forms of various medicines.